Editor: What To Know
- Today they announced that the Company has entered into a licensing and collaboration agreement with King's College London, a leading research university and one of the oldest and most prestigious universities in England.
- “This is the perfect union of our vision at Mahana plus a leading academic institution's desire to bring world-leading research into the hands of patients,” said Robert Paull, co-founder and CEO of Mahana Therapeutics.
- “The digital era has allowed us the opportunity to explore new ways to reach patients and provide them with access to psychological-based therapies that help control symptoms in a more convenient way.
Mahana Therapeutics is a digital therapeutics company reimagining the treatment of chronic diseases. Today they announced that the Company has entered into a licensing and collaboration agreement with King’s College London, a leading research university and one of the oldest and most prestigious universities in England. Mahana has acquired a worldwide exclusive license to an innovative digital therapeutic for the treatment of irritable bowel syndrome (IBS).
Professor Rona Moss-Morris, Head of Psychology Department, Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London led the development of the digital program in collaboration with Trudie Chalder, Professor of Cognitive Behavioural Psychotherapy and Dr. Alice Sibelli both also from King’s, Hazel Everitt, GP and Professor of Primary Care Research, Faculty of Medicine, University of Southampton, and a broad multi-university team. “We spent over 18 years developing and clinically testing a personalized digital CBT program for adult IBS patients,” said Rona Moss Morris. “We believe our multi-center, randomized controlled trial (RCT) of 558 patients is the largest clinical trial ever conducted demonstrating the clinical safety and efficacy of a digital CBT product for IBS.” The trial, with results published in 2019 prestigious medical journal Gut[1], demonstrated that web-based CBT showed substantial and durable IBS symptom severity improvements versus treatment as usual (i.e. doctors visits alone) and also led to reductions in anxiety and depression in patients over three, six and twelve-month time periods.
“The digital era has allowed us the opportunity to explore new ways to reach patients and provide them with access to psychological-based therapies that help control symptoms in a more convenient way. We are thrilled to partner with Mahana Therapeutics. Mahana shares our vision to provide patients in the U.K. and abroad with clinically and cost-effective treatments for gastrointestinal diseases and they have been an amazing collaborative partner,” said Professor Moss-Morris.
“This is the perfect union of our vision at Mahana plus a leading academic institution’s desire to bring world-leading research into the hands of patients,” said Robert Paull, co-founder and CEO of Mahana Therapeutics. “The digital therapeutic developed by Professor Moss-Morris and her colleagues at King’s College London is best-in-class and supported by extensive clinical data. We are excited to bring this important treatment option to patients in the United Kingdom, United States and globally.
Reference
[1] Everitt HA, et al. Gut 2019;0:1–11. doi:10.1136/gutjnl-2018-317805
